RGRashmi Gupta

Rashmi Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rashmi Gupta has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CRISPRi-mediated in vivo gene silencing: a tool for prioritizing drug targets in Mycobacterium abscessus

    by Rashmi Gupta, Breven S. Simcox, Kyle H. Rohde

    Mycobacterium abscessus ( Mab ) is a multidrug-resistant nontuberculous mycobacterium that causes debilitating tuberculosis (TB)-like pulmonary infections for which effective treatment options are lacking. One contributing factor to the poor in vivo efficacy of antibiotics may be the altered vulnerability of drug targets driven by host-specific environmental conditions. To enable validation and prioritization of candidate drug targets in vivo , we exploited CRISPRi (CRi) gene silencing in multiple mouse infection models. Inducible silencing of ftsZ Mab , a previously validated target, and three predicted targets ( leuS Mab , folP Mab , and fusA Mab ) confirmed their essentiality in vitro . We then assessed the in vivo vulnerability of these targets in both immunocompetent C57BL/6N and immunodeficient NOD SCID gamma (NSG) mice by evaluating the impact of CRi silencing on pulmonary mycobacterial burden. In NSG mice, silencing of each of these four genes led to comparable decreases in Mab burden. However, in C57BL/6N mice, the degree of Mab clearance varied among targets, suggesting that immune pressure may influence the outcome of CRi-mediated gene silencing. Notably, repression of fusA Mab yielded a larger decline in mycobacterial burden in C57BL/6N mice despite a lower level of gene silencing in vitro, consistent with the enhanced vulnerability of this target. Overall, this study demonstrated that ftsZ Mab , leuS Mab , folP Mab , and fusA Mab are essential for Mab growth in vitro and, for the first time, validated their vulnerability to inhibition by CRi during infection. These data also identified potential context-dependent target vulnerabilities, which could inform the prioritization of bacterial drug targets and accelerate the development of effective therapeutics for Mab infections.


  • Open Access

    CRISPRi-mediated validation of candidate Mycobacterium abscessus drug targets during host infection

    by Rashmi Gupta, Breven S. Simcox, Kyle H. Rohde

    Mycobacterium abscessus ( Mab ) is a multidrug-resistant nontuberculous mycobacterium that causes debilitating TB-like pulmonary infections for which effective treatment options are lacking. Poor in vivo drug efficacy may stem from altered vulnerability of drug targets driven by host-specific environmental conditions. To enable validation and prioritization of candidate drug targets in vivo , we exploited CRISPRi (CRi) gene silencing in multiple mouse infection models. Inducible silencing of ftsZ Mab , a previously validated target, and three predicted targets ( leuS Mab , folP Mab , fusA Mab ) confirmed their essentiality in vitro . We then assessed the in vivo vulnerability of these targets in both immunocompetent C57BL/6N and immunodeficient NSG mice by assessing the impact of CRi silencing on pulmonary mycobacterial burden. In NSG mice, silencing of all four genes led to comparable decreases in Mab burden. However, in C57BL/6N mice, the degree of Mab clearance varied among targets, suggesting that immune pressure may influence the outcome of CRi-mediated gene silencing. Notably, repression of fusA Mab yielded a larger decline in mycobacterial burden in C57BL/6N mice despite a lower level of gene silencing in vitro , consistent with enhanced vulnerability of this target. Overall, this study demonstrated that ftsZ Mab , leuS Mab , folP Mab , and fusA Mab are essential for Mab growth in vitro and, for the first time, validated their vulnerability to inhibition by CRi during infection. These data also identified potential context-dependent target vulnerabilities, which could inform the prioritization of bacterial drug targets and accelerate the development of effective therapeutics for Mab infections.

  • Open Access

    Mycobacterium abscessus persistence in the face of Pseudomonas aeruginosa antagonism

    by Rashmi Gupta, Martin Schuster, Kyle H. Rohde

    Chronic bacterial infections are responsible for significant mortality and morbidity in cystic fibrosis (CF) patients. Pseudomonas aeruginosa ( Pa ), the dominant CF pathogen, and Mycobacterium abscessus ( Mab ) both cause persistent pulmonary infections that are difficult to treat. Co-infection by both bacterial pathogens leads to severe disease and poor clinical outcomes. To explore understudied interactions between these two CF pathogens, we employed culture- and molecular-based approaches. In a planktonic co-culture model, growth of Pa continued unimpeded, and it exerted a bacteriostatic effect on Mab . Strikingly, exposure of Mab grown in monoculture to cell-free spent supernatant of Pa resulted in a dramatic, dose-dependent bactericidal effect. Initial characterization indicated that this potent Pa -derived anti- Mab cidal activity was mediated by a heat-sensitive, protease-insensitive soluble factor of >3kDa size. Further analysis demonstrated that expression of this mycobactericidal factor requires LasR, a central regulator of Pa quorum sensing (QS). In contrast, ΔLasR Pa was still able to exert a bacteriostatic effect on Mab during co-culture, pointing to additional LasR-independent factors able to antagonize Mab growth. However, the ability of Mab to adapt during co-culture to counter the cidal effects of a LasR regulated factor suggested complex interspecies dynamics. Dual RNAseq analysis of Mab-Pa co-cultures revealed significant transcriptional remodeling of Mab , with differential expression of 68% of Mab genes compared to minimal transcriptional changes in Pa . Transcriptome analysis reflected slowed Mab growth and remodeling of carbon and energy metabolism akin to a non-replicating persister-like phase. A tailored Mab response to Pa was evident by enhanced transcript levels of genes predicted to interfere with alkylquinolone QS signals or provide protection against respiratory toxins and hydrogen cyanide. This is the first study to provide a transcriptome-level view of genetic responses governing the interplay between two important CF pathogens. This will provide insights into interspecies interaction mechanisms which can be targeted to disrupt their communities in a CF lung to improve patient clinical performance. Moreover, identification of a novel antimicrobial natural product with potent cidal activity against Mab will provide a chemical biology tool for identifying new drug targets in Mab .


  • Open Access

    Plakinamine P, A Steroidal Alkaloid with Bactericidal Activity against Mycobacterium tuberculosis

    by Carolina Rodrigues Felix, Jill C. Roberts, Priscilla L. Winder, Rashmi Gupta, M. Cristina Diaz, Shirley A. Pomponi, Amy E. Wright, Kyle H. Rohde

    Tuberculosis is the leading cause of death due to infectious disease worldwide. There is an urgent need for more effective compounds against this pathogen to control the disease. Investigation of the anti-mycobacterial activity of a deep-water sponge of the genus Plakina revealed the presence of a new steroidal alkaloid of the plakinamine class, which we have given the common name plakinamine P. Its structure is most similar to plakinamine L, which also has an acyclic side chain. Careful dissection of the nuclear magnetic resonance data, collected in multiple solvents, suggests that the dimethyl amino group at the 3 position is in an equatorial rather than axial position unlike previously reported plakinamines. Plakinamine P was bactericidal against M. tuberculosis, and exhibited moderate activity against other mycobacterial pathogens, such as M. abscessus and M. avium. Furthermore, it had low toxicity against J774 macrophages, yielding a selectivity index (SI, or IC50/MIC) of 8.4. In conclusion, this work provides a promising scaffold to the tuberculosis drug discovery pipeline. Future work to determine the molecular target of this compound may reveal a pathway essential for M. tuberculosis survival during infection.


  • Open Access

    Exploitation of Mangrove Endophytic Fungi for Infectious Disease Drug Discovery

    by Danielle H. Demers, Matthew A. Knestrick, Renee Fleeman, Rahmy Tawfik, Ala Azhari, Ashley Souza, Brian Vesely, Mandy Netherton, Rashmi Gupta, Beatrice L. Colon, et al.

    There is an acute need for new and effective agents to treat infectious diseases. We conducted a screening program to assess the potential of mangrove-derived endophytic fungi as a source of new antibiotics. Fungi cultured in the presence and absence of small molecule epigenetic modulators were screened against Mycobacterium tuberculosis and the ESKAPE panel of bacterial pathogens, as well as two eukaryotic infective agents, Leishmania donovani and Naegleria fowleri. By comparison of bioactivity data among treatments and targets, trends became evident, such as the result that more than 60% of active extracts were revealed to be selective to a single target. Validating the technique of using small molecules to dysregulate secondary metabolite production pathways, nearly half (44%) of those fungi producing active extracts only did so following histone deacetylase inhibitory (HDACi) or DNA methyltransferase inhibitory (DNMTi) treatment.


  • Open Access

    A sophisticated multi-step secretion mechanism: how the type 3 secretion system is regulated

    by Nicola Barison, Rashmi Gupta, Michael Kolbe

    Many Gram-negative pathogens utilize type 3 secretion systems (T3SSs) for a successful infection. The T3SS is a large macromolecular complex which spans both bacterial membranes and delivers effector proteins into the host cell. The infection requires spatiotemporal control of diverse sets of secreted effectors and various mechanisms have evolved to regulate T3SS in response to external stimuli. This review will describe mechanisms that may control type 3 secretion, revealing a multi-step regulatory strategy. We then propose an updated model of T3SS that illustrates different stages of secretion and integrates the most recent structural and functional data.